Cancer Control (Apr 2023)

Pan-Cancer Study of the Prognosistic Value of Selenium Phosphate Synthase 1

  • Jie Hao,
  • Ao-Yue He,
  • Xu Zhao,
  • Xue-Qin Chen,
  • Qi-Ling Liu,
  • Na Sun,
  • Rong-Qiang Zhang,
  • Ping-Ping Li

DOI
https://doi.org/10.1177/10732748231170485
Journal volume & issue
Vol. 30

Abstract

Read online

Objective: This study sought to determine the mean prognostic usefulness of seleniumphosphate synthase ( SEPHS1 ) by investigating its expression in 33 human malignancies and its relationship to tumor immunity. Methods: The expression of selenophosphate synthase 1 ( SEPHS1 ) in 33 human malignant tumors was examined using the Genotype-Tissue Expression (GTEx), Cancer Genome Atlas (TCGA), and TIMER databases. Furthermore, the TCGA cohort was used to investigate relationships between SEPHS1 and immunological checkpoint genes (ICGs), tumor mutation burden (TMB), microsatellite instability (MSI), and DNA mismatch repair genes (MMRs). To establish independent risk factors and calculate survival probabilities for liver hepatocellular carcinoma (LIHC) and brain lower-grade glioma (LGG), Cox regression models and Kaplan-Meier curves were utilized. Eventually, the Genomics of Cancer Drug Sensitivity (GDSC) database was used to evaluate the drug sensitivity in LGG and LIHC patients with high SEPHS1 expression. Results: Overall, in numerous tumor tissues, SEPHS1 was highly expressed, and it significantly linked with the prognosis of LGG, ACC, and LIHC ( P < .05). Furthermore, in numerous cancers, SEPHS1 expression was linked to tumor-infiltrating immune cells (TIICs), TMB, MSI, and MMRs. According to univariate and multivariate Cox analyses, SEPHS1 expression was significant for patients with LGG and LIHC. Conclusion: High SEPHS1 expression has a better prognosis for LGG, while low SEPHS1 expression has a better prognosis for LIHC. Chemotherapy was advised for LGG patients, particularly for those with high SEPHS1 expression because it can predict how responsive patients will be to 5-Fluorouracil and Temozolomide. This interaction between SEPHS1 and chemoradiotherapy has a positive clinical impact and may be used as evidence for chemotherapy for LGG and LIHC patients.